产品
编 号：F200410
分子式：C32H31F2N3O2
分子量：527.6
分子式：C32H31F2N3O2
分子量：527.6
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 167354-41-8
产品详情
生物活性：
Zosuquidar (LY335979) is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research.
体内研究：
Zosuquidar (intraperitoneal injection; 30, 10, 3, or 1 mg/kg; once daily; 5 d) treatment shows a significant increase in life span.Zosuquidar (intraperitoneal injection; 30 mg/kg; once daily; 5 d) treatment shows the potentiation with a combined of Doxorubicin.Animal Model:Mice implanted with P388/ADR tumors
Dosage:30, 10, 3, or 1 mg/kg
Administration:Intraperitoneal injection; 30, 10, 3, or 1 mg/kg; once daily; 5 days
Result:Exihibited a significantly increased survival compared to the group treated with Doxorubicin alone (P<0.001).
Animal Model:Mice implanted with P388 or P388/ADR murine leukemia cells
Dosage:30 mg/kg
Administration:Intraperitoneal injection; 30 mg/kg; once daily; 5 days
Result:Observed significant antitumor activity against the MDR P388/ADR cell lines when mice were treated with a combined dose of 30 mg/kg LY335979 and 1 mg/kg Doxorubicin (P=0.1).
体外研究：
Zosuquidar (0.3 μM; 48 h) treatment enhances the cytotoxicity of DNR (substrates for P-glycoproteins) in P-glycoproteins active cell lines.Zosuquidar (5-16 μM; 72 h) treatment alone shows high cytotoxic concentration to drug-sensitive and MDR cell lines.
Zosuquidar (LY335979) is a P-glycoprotein (P-gp) inhibitor (Ki=59 nM). Zosuquidar shows anti-tumor activities, and can be used in acute myelogenous leukemia (AML) research.
体内研究：
Zosuquidar (intraperitoneal injection; 30, 10, 3, or 1 mg/kg; once daily; 5 d) treatment shows a significant increase in life span.Zosuquidar (intraperitoneal injection; 30 mg/kg; once daily; 5 d) treatment shows the potentiation with a combined of Doxorubicin.Animal Model:Mice implanted with P388/ADR tumors
Dosage:30, 10, 3, or 1 mg/kg
Administration:Intraperitoneal injection; 30, 10, 3, or 1 mg/kg; once daily; 5 days
Result:Exihibited a significantly increased survival compared to the group treated with Doxorubicin alone (P<0.001).
Animal Model:Mice implanted with P388 or P388/ADR murine leukemia cells
Dosage:30 mg/kg
Administration:Intraperitoneal injection; 30 mg/kg; once daily; 5 days
Result:Observed significant antitumor activity against the MDR P388/ADR cell lines when mice were treated with a combined dose of 30 mg/kg LY335979 and 1 mg/kg Doxorubicin (P=0.1).
体外研究：
Zosuquidar (0.3 μM; 48 h) treatment enhances the cytotoxicity of DNR (substrates for P-glycoproteins) in P-glycoproteins active cell lines.Zosuquidar (5-16 μM; 72 h) treatment alone shows high cytotoxic concentration to drug-sensitive and MDR cell lines.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备